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Results: The group studied consisted o f women 44%, men 56%. BPI is a numerical scale o f  
0-10 assessing the degree o f  pain interference with the normal activities o f  the patient which it 
applies, to which is added information on the gradation o f  the pain, the pain at the time o f  
examination. Starting from the order established after evaluation o f  maximum intensity o f  the pain 
score 6-30%, followed by the score 8-15%, scores 9 and 10 - 10-12%. When assessing the 
minimum level o f  pain intensity score o f 2 to 23% and score 4 to 20 %, which ranks the most 
frequently encountered in patients investigated. Usual level o f  pain intensity score highlights the 
prevalence o f  6 and 8 with 20%, followed by the score 5 to 18%, the other scores were determined 
from a minimum o f  patients. Depending on the type o f treatment: 79% were receiving 
chemotherapy, chemo-radiotherapeutic treatment 5%, hormone therapy 2% and unspecified 14%. 
According to the step by step antalgic treatment, elaborated by WHO: analgesic stage administered 
-7% stage I, stage II- 23% and stage III - 70 %.
Conclusion: Analyzing all the features o f chronic pain by using the BPI questionnaire in the 
study o f  cancer patients, we determined that although in theory the current therapeutic methods and 
applying rational (W HO principles) would allow excellent results in almost 95% o f patients, but 
cancer pain remains untreated satisfactory in many situations
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Introduction: Hodgkin lymphoma is a malignant tumor o f  the lymphatic system. Hodgkin's 
disease occurs predominantly in young adults and is one o f  the most curable malignancies. With 
current treatment approaches, most patients achieve a lasting complete remission, but there is a high 
risk o f  developing in these patients’ secondary malignant tumors, and the mortality is associated 
with both radiotherapy and chemotherapy.
Purpose and objectives: Researching metachronous malignancies in patients with Hodgkin 
lymphoma and studying the frequency o f  their occurrence, depending o f  the age, sex, clinical 
stages, histological forms, the administrated treatment for Hodgkin lymphoma and also the time 
period for developing secondary malignancies.
Materials and Methods: Our study is based on 53 patients diagnosed and treated for 
Hodgkin Lymphoma in Oncological Institute o f  Republic o f  Moldova, all the patients where in 
complete remission when they developed secondary malignancy. In our study where 22 men and 31 
women, with ages between 4 and 81 years.
Results: According to our study the number o f  patients diagnosed with Hodgkin's was the 
highest in the age o f  11-21 for women (24,5%) and 21-31 for men (24,5%). The mix cellular form 
o f tumors was the most frequent (43,39%). The metachronous tumors are mostly revealed in the 
stage IIA (39, 62%) o f  the disease. Our research carried out that there is a prevalence o f  a combined 
chemo-radiotherapy method o f  treatment (52.83%). The maximum risk o f  developing secondary 
metachronous tumors occurs over 11 to 20 years (46%), and the most frequently diagnosed tumors 
where lung cancer (22,64%), gastric cancer (16,98%), breast cancer( 13,20%).
Conclusions: After treatment for Hodgkin's lymphoma in patients may develop secondary 
metachronous tumors that occur more frequently in women aged 21-40 years at diagnosis o f  Hodgkin 
lymphoma. Metachronous secondary tumors are identified mainly in patients diagnosed with stage IIA 
Hodgkin lymphoma, histological variant most commonly diagnosed as mixed cellularity. The method o f 
treatment was chosen for the majority o f  patient’s chemo-radiotherapeutic. Period o f  development o f 
secondary tumors is 11-20 years after treatment for Hodgkin's lymphoma. Secondary malignancies after 
Hodgkin Lymphoma can have different location.
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